About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

News

August 9, 2018
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results

August 2, 2018
Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET

June 19, 2018
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

Events

August 9, 2018
Second Quarter 2018 Financial Results Call

May 10, 2018
First Quarter 2018 Financial Results Call

April 26, 2018
Fourth International Vatican Conference

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology